Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The slow roll-out of the world’s first malaria vaccine

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Nature 612, S48-S49 (2022)

doi: https://doi.org/10.1038/d41586-022-04343-7

This article is part of Nature Outlook: Children‘s health, an editorially independent supplement produced with the financial support of third parties. About this content.

Updates & Corrections

  • Correction 19 January 2023: This Outlook article misrepresented the results of ref. 3. The 60% efficacy of the protection of the combination of RTS,S with chemoprevention was relative to either intervention on its own, not the efficacy of the combination itself.

References

  1. RTS,S Clinical Trials Partnership. Lancet 386, 31–45 (2015).

    Article  PubMed  Google Scholar 

  2. Hogan, A. B., Winskill, P. & Ghani, A. C. PLoS Med. 17, e1003377 (2020).

    Article  PubMed  Google Scholar 

  3. Chandramohan, D. et al. N. Engl. J. Med. 385, 1005–1017 (2021).

    Article  PubMed  Google Scholar 

  4. Datoo, M. S. et al. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(22)00442-X (2022).

    Article  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links